Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine

Abroad (travel likely)RecruitingPHASE3

Conditions

COVID-19

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Invivyd Investigative Site, Overland Park, Kansas, United States
Contact: Study coordinator (Study Inquiry) · clinicaltrials@invivyd.com · 781-819-0080

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Convalescent Plasma as a Possible Treatment for COVID-19

COVID-19

Abroad (travel likely)RecruitingPHASE2

Chicago, United States

A Study of Apabetalone in Subjects With Long -COVID

Post-Acute COVID-19 Syndrome

Abroad (travel likely)RecruitingPHASE2, PHASE3

Amman, Jordan · Al Mubarraz, Saudi Arabia

Immunity and Safety of Covid-19 Synthetic Minigene Vaccine

Pathogen Infection Covid-19 Infection

Abroad (travel likely)RecruitingPHASE1, PHASE2

Shenzhen, China

The Effect of COVID-19 Pandemic on Adolescent and Young Adult Cancer Patients and Survivors

COVID-19 Infection · Hematopoietic and Lymphoid Cell Neoplasm · Malignant Solid Neoplasm

Abroad (travel likely)Recruiting

Houston, United States